Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by 2skytracker2on Jun 12, 2012 9:24pm

298 Views

Post# 20006364

And Next !!

So....the next step will be to issue more shares, go back to the market to raise cash so they can carry on drilling. They will most likely issue 50 to 60 million @ .30.................thats $18 million , which may be enough to rework mani# 1 and finish what needs to be done with Flami......... this of course will dilute our shares to one half of there current value again. Only my opinion of course. I'm choked with this outfit.....but im in too deep now.

Good Luck to all!!

Bullboard Posts

Hyundai partners with BlackBerry for next-gen digital cockpit platform